SeaStar to begin study of immunomodulating device in Covid-19 patients

SeaStar Medical aims to evaluate the safety and efficacy of Selective Cytopheretic Device in Covid-19 patients with acute respiratory distress syndrome and acute kidney injury. Credit: James Heilman, MD.



  • SeaStar